Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Protocol: Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma
Study: Multicenter, single-arm, phase II trial Newly diagnosed multiple myeloma (N:123) High-risk cytogenetic abnormalities: 0:56 1:46 2:24 patients Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) plus AHCT, and Dara-KRd consolidation Efficacy:
New Protocol: SubQ daratumumab – carfilzomib – dexamethasone for myeloma
Study: Single arm cohort study Relapsed or refractory multiple myeloma Prior 1 to 3 lines therapy Daratumumab 1800 mg SC, hyaluronidase 30000 units SC, carfilzomib IV and dexamethasone peroral Efficacy: